Phase 1 Completed N=56 Randomized Double-blind Treatment

The Effects of Smell on Mood and Physical Responses

Stress · Anxiety · Depression

Source: ClinicalTrials.gov NCT00097253 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2010

Primary outcomePrimary: Cortisol and Catecholamine Production — 0.107; 0.119; 0.107; 43.5 pg/ml (log 10) — p=0.83

Summary

The purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.

Outcome Measures

Outcome	Result	p-value
PRIMARY Cortisol and Catecholamine Production	0.107; 0.119; 0.107; 43.5; 44.3; 38.3	0.83
PRIMARY Immune Function	3.706; 3.622; 3.623; 1.777; 1.734; 1.787	0.10
PRIMARY Skin Barrier Repair	23.21; 24.33; 22.11; 15.64; 17.78; 16.82	0.60
PRIMARY Immune Function: Delayed Hypersensitivity to Candida(DTH)	10.84; 17.39; 12.40	0.014 sig

Eligibility Criteria

Inclusion Criteria

Healthy adults with a normal sense of smell

Exclusion Criteria

Treatment with medication that has immunological or endocrinological consequences
Chronic health problems that affect immune or endocrine systems
Allergy to perfume or cosmetics
Problems with sense of smell
Respiratory problems
Smoker
Current active asthma
Use of psychoactive drugs or mood-altering medication
History of anxiety disorder, major depression, bipolar disorder, schizophrenia, or other psychotic disorders
History of chest pain or ventricular fibrillation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00097253). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.